Company / Operating Cash Flow per Share
LENZ Therapeutics, Inc. Operating Cash Flow per Share History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$2.51
FY2025
5-year range
-$30.82 / -$1.60
FY2021-FY2025
Trend
+9.9%
vs FY2024
Sector context
#162 of 212
Health Care
What the data says
LENZ Therapeutics, Inc.'s operating cash flow per share of $-2.51 is lower than 76% of companies in the Health Care sector (FY2025). Improved from $-30.82 to $-2.51 over the past 2 years.
Based on SEC 10-K filings.
-2.51 in FY2025.
Improved from $-30.82 to $-2.51 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 212This company -$2.51 Sector average -$14.72
▼
+82.9% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share increased 9.9% year-over-year.
- Ranks #162 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2022.
- Lowest operating cash flow per share in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 4.71 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.51 | +9.9% |
| FY2024 | -$2.79 | +90.9% |
| FY2023 | -$30.82 | -1822.3% |
| FY2022 | -$1.60 | +12.3% |
| FY2021 | -$1.83 | +52.1% |
| FY2020 | -$3.82 | - |
As of FY2025 · SEC 10-K · Updated Mar 28, 2026